Recent clinical trials of veliparib, both as monotherapy and in combination with a variety of chemotherapeutic agents or radiation therapy, have provided data in support of veliparib's activity in BRCA‐mutated tumors.27, 36, 37, 38, 39, 40, 41, 42, 43 In a phase 2 study of veliparib as monotherapy in patients with recurrent ovarian cancer and germline BRCA1 and BRCA2 mutations,27 26% of patients showed an objective response (n = 50; 90% CI: 16–38%; CR: 2; PR: 11) with a median progression‐free survival of 8.2 months. This evidence concerns the gene BRCA1 and ovarian carcinoma.